Results 181 to 190 of about 88,362 (256)

A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds

open access: yesHealth Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims Acne vulgaris is a frequent skin disorder, affecting a large part of the population worldwide, and strongly influencing not only the physical but also the mental aspects of health. The choice of therapy for acne vulgaris is a very difficult one because the multifactorial causality of the disease and interindividual ...
Mobina Tajdari   +5 more
wiley   +1 more source

Venous Thromboembolism in Aggressive B‐Cell Lymphoma Patients Treated with CD19 CAR‐T Therapy: Single‐Institution Study

open access: yeseJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background Large B‐cell lymphomas (LBCLs) are a common subtype of non‐Hodgkin lymphomas. CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy has revolutionized LBCL treatment, with high remission rates but also significant toxicities, including cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS).
Neha Venkatesh   +9 more
wiley   +1 more source

Transformation and causes of death in follicular lymphoma: A Finnish nationwide population-based study. [PDF]

open access: yesBr J Haematol
Kalashnikov I   +6 more
europepmc   +1 more source

Clinical characteristics of duodenal-type follicular lymphoma. [PDF]

open access: yesDiscov Oncol
Wang L, Shen W, Zhang X, Xue L, Hu B.
europepmc   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

open access: yesMicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo   +5 more
wiley   +1 more source

The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification. [PDF]

open access: yesBr J Haematol
Picardi M   +8 more
europepmc   +1 more source

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy